A randomized, double-blind, crossover, placebo-controlled clinical trial to assess effects of the single ingestion of a tablet containing lactoferrin, lactoperoxidase, and glucose oxidase on oral malodor by Manabu Nakano et al.
RESEARCH ARTICLE Open Access
A randomized, double-blind, crossover,
placebo-controlled clinical trial to assess
effects of the single ingestion of a tablet
containing lactoferrin, lactoperoxidase, and
glucose oxidase on oral malodor
Manabu Nakano1*, Eiju Shimizu2, Hiroyuki Wakabayashi1, Koji Yamauchi1 and Fumiaki Abe1
Abstract
Background: The main components of oral malodor have been identified as volatile sulfur compounds (VSCs)
including hydrogen sulfide (H2S) and methyl mercaptan (CH3SH). VSCs also play an important role in the progression of
periodontal disease. The aim of the present study was to assess the effects of the single ingestion of a tablet
containing 20 mg of lactoferrin, 2.6 mg of lactoperoxidase, and 2.6 mg of glucose oxidase on VSCs in the mouth.
Method: Subjects with VSCs greater than the olfactory threshold in their mouth air ingested a test or placebo
tablet in two crossover phases. The concentrations of VSCs were monitored at baseline and 10 and 30 min after
ingestion of the tablets using portable gas chromatography.
Results: Thirty-nine subjects were included in the efficacy analysis based on a full analysis set (FAS). The concentrations
of total VSCs and H2S at 10 min were significantly lower in the test group than in the placebo group (−0.246 log
ng/10 ml [95 % CI −0.395 to −0.098], P = 0.002; −0.349 log ng/10 ml; 95 % CI −0.506 to −0.192; P < 0.001,
respectively). In the subgroup analysis, a significant difference in the concentration of total VSCs between
the groups was also observed when subjects were fractionated by sex (male or female) and age (20–55 or
56–65 years). The reducing effect on total VSCs positively correlated with the probing pocket depth (P = 0.035).
Conclusions: These results suggest that the ingestion of a tablet containing lactoferrin, lactoperoxidase, and glucose
oxidase has suppressive effects on oral malodor.
Trial registration: This trial was registered with the University Hospital Medical Information Network Clinical Trial
Registry (number: UMIN000015140, date of registration: 16/09/2014).
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Background
Oral malodor is a common condition and a source of
concern among a large number of people. When oral
malodor is severe or long-standing, it may have a nega-
tive impact on self-confidence and social interactions
[1]. A previous study indicated that oral malodor is the
third most common reason, following dental caries and
periodontal disease, to visit the dentist [2]. Volatile sul-
fur compounds (VSCs), mainly composed of hydrogen
sulfide (H2S) and methyl mercaptan (CH3SH), are the
main causes of oral malodor [3]. VSCs occur due to the
metabolic degradation of sulfur-containing amino acids
by the lyases of oral anaerobes [4]. A previous study re-
ported a strong correlation between periodontal condi-
tions and the concentrations of VSCs [4]. VSCs have
also been identified as toxic agents that accelerate the
progression of periodontal disease by increasing the per-
meability of the oral mucosa [5], suppressing the synthe-
sis of collagen [6] and inhibiting the proliferation of
osteoblasts [7].
Different treatment strategies including rinsing with
antimicrobial agents have been proposed for the man-
agement of oral malodor [8, 9]. Although an anti-
microbial mouth rinse containing chlorhexidine was
previously shown to effectively suppress oral malodor
[8], the use of chlorhexidine for extended periods of
time has been associated with side effects including
tooth and tongue staining and a bad taste [8, 10].
Lactoferrin (LF) and lactoperoxidase (LPO) are glyco-
proteins that are found in milk, saliva, and other exo-
crine secretions [11–14]. LF and LPO have been shown
to exert antimicrobial effects against oral pathogens. LF
exhibits antibacterial effects against periodontopathic
bacteria, including Porphyromonas gingivalis and Aggre-
gatibacter actinomycetemcomitans [12, 15, 16], and
antibiofilm effects against P. gingivalis and Prevotella
intermedia [17]. LPO catalyzes the hydrogen peroxide-
dependent oxidation of thiocyanate (SCN−) to hypothio-
cyanite (OSCN−), which is a potent antimicrobial agent
against bacteria, fungi, and viruses [13, 14]. This anti-
microbial system is called the LPO system. Glucose oxi-
dase (GO), which is used in the food industry, has been
employed as a source of H2O2 [18].
Glucose þ O2→
GO




A composition containing LPO, GO, glucose, and cit-
rate buffer salts was previously found to exhibit in vitro
bactericidal activity in the presence of saliva or SCN−
[19]. A preliminary in vivo study suggested that this
composition was effective for reducing oral malodor
[19]. In a previous clinical trial that enrolled 15 healthy
volunteers aged 26–54 years, sucking a trial tablet con-
taining 100 mg of LF, 1.8 mg of LPO, and 24 mg of
Sumizyme PGO which was composed of dextrin and
GO, had short-term suppressive effects on the concen-
trations of VSCs in mouth air [20]. The underlying
mechanisms of action reducing VSCs were suggested to
involve the antimicrobial effects of LF and the LPO sys-
tem [20] in addition to the inactivating effects of the
LPO system on bacterial lyases involved in the produc-
tion of VSCs [21]. Based on these findings, a powder
composition including 20 mg of LF, 2.6 mg of LPO, and
2.6 mg of GO was developed for functional food prod-
ucts [22]. Several commercial food products including
this composition were recently launched in Japan.
The aim of the present study was to assess the effects
of the single ingestion of a commercial tablet containing
20 mg of LF, 2.6 mg of LPO, and 2.6 mg of GO on oral
malodor. We enrolled 40 healthy adults in this trial,
which was conducted on a larger scale than a previous
related clinical trial [20]. We also investigated the rela-
tionships between the treatment effects of the tablet and
periodontal conditions of the subjects.
Methods
Study food
A commercial tablet (Morinaga Orabarrier, Morinaga
Milk Industry Co., Ltd., Tokyo, Japan) was used as the
test tablet. The test tablet contained 20 mg of LF, 2.6 mg
(≥ 25 units) of LPO, and 2.6 mg (≥ 25 units) of GO as
the active ingredients. The test tablet also contained glu-
cose, citric acid, and sodium citrate, which support the
effects of the active ingredients. The other ingredients in
the test tablet were reduced palatinose, reduced sugar
syrup, sorbitol, cellulose, calcium stearate, silicon diox-
ide, flavor, and sucralose. A placebo tablet contained
cornstarch and coloring materials (gardenia pigment) in-
stead of LF, LPO, GO, glucose, citric acid, and sodium
citrate. LF (Morinaga Milk Industry Co., Ltd., Tokyo,
Japan) and LPO (Tatua, Morrinsville, New Zealand) were
purified from bovine milk. GO (Sumizyme PGO, Shin-
Nihon Chemical, Aichi, Japan) was composed of dextrin
and GO obtained from Penicillium chrysogenum. These
test and placebo tablets were circular in shape with a
diameter of 15 mm and thickness of 6 mm. The tablets
were also identical in weight, texture, and appearance,
but had slightly different tastes due to their ingredients.
Study design and subjects
This was a single center, randomized, double-blind,
placebo-controlled, crossover study conducted in Japan.
The study was conducted in accordance with Helsinki
Declaration of 1975 and as revised in 2013. The study
protocol was reviewed and approved by the Research
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Ethics Committee of Kenshokai (no. OBHALI01, on
August 8, 2014). The study was performed at Shimizu
Dental Clinic in Takasaki between October 2014 and
May 2015 by following the CONSORT guidelines for
clinical trial Additional file 1.
Individuals who had been referred to Shimizu Dental
Clinic were recruited, and screened after providing written
informed consent. Inclusion criteria were all adults aged
20 to 65 who had VSCs greater than the olfactory thresh-
old (H2S > 1.5 ng/10 ml and CH3SH > 0.5 ng/10 ml air)
in mouth air, which were measured using portable gas
chromatography as described below. Exclusion criteria
were: 1) Subjects with severe liver, kidney, heart, lung,
gastrointestinal, blood, endocrine, and metabolic dis-
eases. 2) Subjects receiving treatments for dental dis-
eases such as caries and periodontal disease. 3) Subjects
treated with antibiotics in the past month. 4) Subjects
who participated in other clinical studies in the past
month. 5) Subjects with a history of allergies to milk
and/or dairy products. 6) Subjects who were pregnant or
lactating, or those who were expecting to become preg-
nant during the study. 7) Subjects judged inappropriate
for the study by the investigator. Subjects were ran-
domly assigned to one of two groups, initially at a 1:1
ratio. On the first test day, subjects in group A (n = 20)
ingested the test tablet, while subjects in group B (n = 20)
ingested the placebo tablet. After a 1–4-week washout,
each subject ingested the alternative tablet to that on the
first test day. No significant changes were made to the
methods after trial commencement.
Outcome and clinical assessments
Oral malodor measurements were conducted in refer-
ence to the protocol described previously [23, 24]. On
the day of the assessment, each subject was asked to re-
frain from oral activities including eating, drinking,
smoking, and using oral-hygiene practices from the time
they woke up until the end of the assessment. Concen-
trations of VSCs at the baseline were analyzed with a
portable gas chromatograph (OralChroma®, FIS Inc.,
Japan) [24], which was calibrated before starting the
study. According to the manufacturer’s instructions, sub-
jects were instructed to keep a disposable plastic syringe
in their mouth for 30 s. A sample of their mouth air was
taken, and 0.5 ml of sample air was injected into Oral-
Chroma. The concentrations of H2S and CH3SH were
measured in each sample. We confirmed correct peak
assignments for VSCs in the chromatograms using rele-
vant software (OralChroma data manager, FIS Inc.,
Japan) [24]. Two OralChroma readings were taken at
each time point and the calculated average was recorded
as ng/10 ml. The concentration of total VSCs was ob-
tained as the sum of the H2S and CH3SH concentra-
tions. After the VSC analysis at baseline, each subject
was instructed to suck the test or placebo tablet without
chewing or swallowing it. The sucking time was mea-
sured by the examiner. The concentrations of VSCs were
measured 10 and 30 min after ingestion of the tablet.
On the first test day, all subjects were also clinically
evaluated for the following periodontal measurements
after a series of oral malodor assessments; number of
teeth, probing pocket depth (PPD), and bleeding on
probing (BOP) [25]. One well-trained examiner per-
formed these assessments. PPD and BOP were entirely
measured in each tooth. PPD measurements were re-
corded as the deepest pocket depth to the nearest
millimeter.
The primary endpoint was the concentration of total
VSCs at 10 min. The secondary endpoints were the con-
centrations of H2S and CH3SH.
Randomization and blinding procedure
The independent registration center (Morinaga Milk
Industry) registered and randomized the subjects. The
registration center generated a random sequence using
a computer by the permuted block method (block size
of 4). The allocation ratio was 1:1. The allocation se-
quence was concealed from study subjects, the dentist,
co-medicals, data manager, and statistical analyst. Ac-
cording to the allocation sequence, the registration cen-
ter gave a number to the test foods and chronologically
assigned subjects to the test food number. After all data
were fixed, the allocation sequence was broken.
Statistical analysis
The sample size was set to 40, which was the maximum
possible entry number during the study period. All ana-
lyses were based on the intention-to-treat principle.
The concentrations of total VSCs, H2S, and CH3SH did
not show a normal distribution and were, thus, trans-
formed logarithmically to approximate a normal distri-
bution and obtain equal variance. We used linear
mixed models to analyze data for total VSCs, H2S, and
CH3SH. The fixed effects were treatment, period, and
pretreatment values, while the random effect was sub-
jects. The degree of freedom was adjusted by the
Kenward-Roger method. We assessed carry-over effects
by adding treatment-by-period interactions to the linear
mixed model. In the subgroup analysis, we divided sub-
jects into two groups by the median of continuous
background data. We used Pearson’s correlation to as-
sess the relationship between the change in total VSCs
from the baseline and dental clinical parameters. SAS
9.4 and JMP 9.0 (SAS Institute Inc., North Carolina,
US) was used for all analyses. Two-sided P < 0.05 was
considered significant for all tests.
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Results
The flow of our subjects throughout the study is
shown in Fig. 1. Fifty-eight males and females were en-
rolled between October 2014 and May 2015. Forty
subjects were randomized to group A (n = 20) and
group B (n =20). After registration of the 40 eligible
subjects, enrollment to the study ended in May 2015,
and the study was completed in May 2015. Three of
the subjects in group A did not complete the study.
Two were unable to visit the clinic because of their
circumstances. One did not ingest the tablet on the
second test day because the investigator judged the
concentration of VSCs at the baseline to be insuffi-
cient. Therefore, 39 subjects were included in the effi-
cacy analysis based on a full analysis set (FAS). One
subject in group B was excluded from the efficacy
analysis because the concentration of VSCs at the
baseline on the first test day was below the olfactory
threshold.
The demographic and baseline characteristics of the
full analysis set are listed in Table 1. The mean age was
49.4 years, and 64.1 % were female. The mean number
of teeth was 26.9, the average PPD was 4.2 mm, and the
average BOP was 15.1 %. The average sucking times in
the test and placebo groups were 343.7 ± 118.2 s (179–
665 s) and 341.5 ± 130.3 s (190–630 s), respectively. No
significant differences were observed in sucking times
between the test and placebo tablets.
Efficacy
The effects of the test and placebo tablets on the con-
centrations of total VSCs, H2S, and CH3SH 10 and
Fig. 1 Flow diagram of subjects throughout the study
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30 min after their ingestion are summarized in Table 2.
The concentration of total VSCs at 10 min was signifi-
cantly lower in the test group than in the placebo
group (adjusted difference −0.246 log ng/10 ml; 95 %
CI −0.395 to −0.098; P = 0.002). No significant differ-
ences were observed in the concentrations of total
VSCs at 30 min between the test and placebo groups
(P = 0.199). The concentrations of H2S at 10 min were
significantly lower in the test group than in the placebo
group (adjusted difference −0.349 log ng/10 ml; 95 %
CI −0.506 to −0.192; P < 0.001). No significant differences
were noted in the concentrations of H2S at 30 min be-
tween the groups (P = 0.066). Significant differences were
not found in the concentrations of CH3SH at 10 and
30 min between the two groups. The differences observed
in the concentrations of CH3SH between the groups ap-
peared to be slightly higher at 30 min than at 10 min. The
concentrations of total VSCs, H2S, and CH3SH in both
groups were significantly lower at 10 and 30 min than at
the baseline. The average values (not estimated) of total
VSCs, H2S, and CH3SH are shown in Additional file 2:
Figure S1.
No significant interaction was observed between treat-
ment and period (data not shown). This result suggested
that carryover effects were not present. The concentra-
tions of VSCs in groups A and B were inversely related
between days 1 and 2, showing almost similar changes
(Additional file 3: Figure S2).
Changes in the concentrations of VSCs in each of the
39 subjects examined are shown in detail in Fig. 2. The
olfactory thresholds of H2S and CH3SH were previously
reported to be 1.5 and 0.5 ng/10 ml (0.18 and −0.30 log
ng/10 ml) mouth air, respectively [26]. The number of
subjects with concentrations of H2S lower than the ol-
factory threshold was significantly higher in the test
group (61.5 % or 24/39 at 10 min, 59.0 % or 23/39 at
30 min) than in the placebo group (31.4 % or 11/35 at
10 min, 28.6 % or 10/35 at 30 min), according to the
chi-squared test (P = 0.010 at 10 min, P = 0.009 at
30 min). The number of subjects with concentrations of
CH3SH lower than the olfactory threshold was also
higher in the test group (51.3 % or 20/39 at 10 min,
66.7 % or 26/39 at 30 min) than in the placebo group
(42.9 % or 15/35 at 10 min, 51.4 % or 18/35 at 30 min),
and no significant differences were observed between
the groups at 10 min (P = 0.468) or 30 min (P = 0.183).
The percentages of subjects with concentrations of
CH3SH lower than the detection limit (=0 ng/10 ml)
were 17.9 % (7/39) at 10 min and 43.6 % (17/39) at
30 min in the test group, and 20.0 % (7/35) at 10 min
and 25.7 % (9/35) at 30 min in the placebo group,
respectively.
The results of the subgroup analysis for outcomes are
shown in Fig. 3. The difference in the reduction of VSCs
from the baseline to 10 min between the test and pla-
cebo groups was adopted as the treatment effect. The
treatment effect on total VSCs and H2S did not signifi-
cantly differ when subjects were fractionated by sex and
age.
The results of a correlation analysis among the effects
on total VSCs, PPD, BOP, and age of subjects are
shown in Table 3. The reducing effect on total VSCs
positively correlated with PPD (r = 0.358, P = 0.035). A
Table 2 Effects of test and placebo tablets on total VSCs, H2S,
and CH3SH 10 and 30 min after their ingestion
Outcomes Group LS mean ± SEa Differenceb (95 % CI) P-value
Primary outcome
Total VSCs
10 min Test 0.115 ± 0.078 −0.246 0.002
Placebo 0.362 ± 0.081 (−0.395 to 0.098)
30 min Test 0.173 ± 0.086 −0.136 0.199
Placebo 0.309 ± 0.090 (−0.348 to 0.075)
Secondary outcomes
H2S
10 min Test −0.085 ± 0.083 −0.349 < 0.001
Placebo 0.263 ± 0.086 (−0.506 to 0.192)
30 min Test 0.056 ± 0.080 −0.171 0.066
Placebo 0.226 ± 0.084 (−0.353 to 0.012)
CH3SH
10 min Test −0.635 ± 0.129 −0.044 0.747
Placebo −0.591 ± 0.134 (−0.321 to 0.233)
30 min Test −1.070 ± 0.141 −0.265 0.163
Placebo −0.806 ± 0.149 (−0.641 to 0.112)
aThe concentration (log ng/10 ml) of VSCs estimated using a linear
mixed model
bDifference (log ng/10 ml) in the LS mean
LS least square
Table 1 Demographic and baseline characteristics of the full
analysis set (FAS)
Parameters Values




Clinical parameters (mean ± SD)
Number of teeth 26.9 ± 2.8
PPD1 4.2 ± 0.5
BOP2 15.1 ± 20.0
1Probing pocket depth (mm)
2Bleeding on probing (% of teeth)
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correlation was not detected between the treatment ef-
fect on total VSCs and BOP. Age positively correlated
with PPD (r = 0.603, P < 0.001), whereas no correlation
was observed for age and the treatment effect on total
VSCs.
We investigated the influence of the sucking time of
the test tablet on suppressing the concentration of
VSCs by adding a treatment-by-sucking time inter-
action to the linear mixed model. Regarding the
concentration of total VSCs at 10 min, the interaction
was not significant (P = 0.196).
Safety
General conditions were obtained by interviewing sub-
jects on each day of the assessment. One subject in the
placebo group had cold-like symptoms during one of the
washout periods, which did not appear to be related to




Fig. 2 Changes in VSC concentrations in each of the 39 subjects. (a, b) Total VSCs, (c, d) H2S, and (e, f) CH3SH were measured at the baseline and
10 and 30 min after the ingestion of the test tablet (a, c, e) and placebo tablet (b, d, f). The olfactory thresholds of H2S (1.5 ng/10 ml ≈ 0.18 log
ng/10 ml) and CH3SH (0.5 ng/10 ml ≈ −0.30 log ng/10 ml) are shown in broken lines
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no adverse events related to the treatment were ob-
served in any of the 40 subjects during the study.
Discussion
This randomized clinical trial was designed to evaluate
the efficacy of the single ingestion of a commercial tablet
containing 20 mg of LF, 2.6 mg of LPO, and 2.6 mg of
GO on oral malodor. Our results demonstrated that oral
malodor in the general population was lower following
the single ingestion of a tablet containing LF, LPO, and
GO than a placebo tablet. As for the primary outcome,
the concentration of total VSCs at 10 min was signifi-
cantly lower in the test group than in the placebo group.
Furthermore, similar results were obtained for the con-
centrations of H2S and total VSCs. It was estimated that
the test tablet reduced the concentrations of total VSCs
and H2S in the mouth by approximately 57 % (≈10
–0.246)
and 45 % (≈10–0.349) that of the placebo tablet, respect-
ively. No significant differences were observed in the
concentrations of CH3SH at 10 and 30 min between the
groups; however, the difference noted in the concentra-
tion of CH3SH at 30 min appeared to be slightly greater
than that at 10 min. The proportion of CH3SH to total
VSCs was smaller than that to H2S, and may be one of
the reasons why a significant difference was not noted in
CH3SH concentrations. The test and placebo tablets
both significantly reduced the concentration of VSCs at
10 and 30 min to lower than that at the baseline. The
suppressive effects of the placebo tablet may also have
been one of the reasons why significant differences were
not observed between the two groups at 30 min.
VSCs are produced from sulfur-containing amino
acids by oral anaerobes. The effects of many antimicro-
bial agents on oral malodor have been reported previ-
ously [5]. LF and the LPO system, consisting of LPO,
GO, glucose, and SCN−, exert in vitro antibacterial ef-
fects against oral pathogens [12, 19]. We consider these
antibacterial effects to be weaker than those of antibi-
otics which might affects indigenous bacteria and cause
Fig. 3 Subgroup analyses for primary and secondary outcomes. 1Difference between the test and placebo groups in the extent of reductions in
the concentration of total VSCs from the baseline to 10 min after the ingestion of tablets
Table 3 Pearson correlations between effects on total VSCs and
parameters for the clinical assessment
Parameter vs. Parameter r P-value
PPDa ΔΔTotal VSCsb 0.358 0.035
BOPc ΔΔTotal VSCs 0.273 0.113
Age ΔΔTotal VSCs 0.200 0.249
Age PPD 0.603 < 0.001
aThe mean value of the probing pocket depth (mm) of each tooth
bReducing effect on total VSCs; Differences between the test and placebo
groups in the extent of reductions in the concentration of total VSCs from the
baseline to 10 min after ingestion of the tablets
cBleeding on probing (% of teeth)
Nakano et al. BMC Oral Health  (2016) 16:37 Page 7 of 10
superinfections. In a previous clinical trial, terminal re-
striction fragment length polymorphism findings sug-
gested that a tablet containing LF, LPO, and GO reduced
one fragment assigned to bacterial species including
VSC-producing bacteria [20]. In spite of this moderate
antibacterial effect, the suppressive effects of the active
ingredients on VSCs were demonstrated in the present
and previous studies. A recent in vitro study reported
that the LPO system exhibited inactivation activity
against the bacterial lyases related to the production of
VSCs [21]. Inactivation activity may be the main con-
tributor to suppressive effects on VSCs. Thus, the test
tablet immediately exerted suppressive effects on oral
malodor. The reproduction of lyases by viable bacterial
cells may gradually weaken suppressive effects.
Previous studies reported that a tablet containing LF,
LPO, and GO significantly suppressed the concentration
of VSCs 2 h after its ingestion to less than that at the
baseline [20, 22]. In the present study, the concentration
of total VSCs in the test group was constantly low from
10 min to 30 min. The concentrations of H2S and
CH3SH were lower than the olfactory threshold at
10 min in more than half of the subjects in the test
group. The percentage of subjects in the test group with
concentrations lower than the olfactory threshold at
30 min was nearly the same as that at 10 min. These re-
sults suggest that the suppressive effects of the tablet
containing LF, LPO, and GO on oral malodor persisted
for some time.
The test tablet contained glucose, citric acid, and so-
dium citrate, which support the effects of the active in-
gredients. Glucose, citric acid, and sodium citrate were
unlikely to have exerted suppressive effects on VSCs be-
cause they are known not to exhibit antibacterial activity
against periodontal bacteria [19] or inactivation effects
on bacterial lyases involved in the production of VSCs
[21]. The placebo tablet contained cornstarch and color-
ing materials (gardenia pigment), which were added as
replacements. Although digested starch may be a source
of a cariogenic biofilm, previous in vitro oral biofilm and
in vivo studies reported that starch was markedly less
cariogenic than sucrose [27, 28]. Furthermore, we con-
sidered the influence of cariogenic biofilm formation on
VSC production to have been negligible in the short
term in the present study because biofilm formation re-
quires a long period of time and most cariogenic species
do not play a role in the production of VSCs [2]. The
placebo tablet exerted some suppressive effects on oral
malodor. To the best of our knowledge, the suppressive
effects of the ingredients of the placebo tablet including
cornstarch and coloring materials on oral malodor have
not been reported previously. On the other hand, many
studies demonstrated that tongue cleaning reduced the
amount of tongue coating and number of oral bacteria,
thereby effectively improving oral malodor [2, 5, 29].
Another previous clinical trial suggested that a placebo
tablet without active ingredients reduced VSCs in the
short term through its mechanical cleaning effect [30].
Therefore, the suppressive effects of the placebo tablet
on oral malodor in the present study may have been due
to its mechanical cleaning effects. We assumed that the
test tablet suppressed VSCs not only through the anti-
microbial activities of LF and the LPO system against
VSC-producing bacteria, but also by mechanical clean-
ing during sucking.
The concentration of total VSCs was significantly
lower 10 min after ingestion of the previous trial tablet,
which contained 100 mg of LF, 1.8 mg of LPO, and
24 mg of Sumizyme PGO, than the placebo tablet [20].
In the present study, the concentration of VSCs was sig-
nificantly lower 10 min after ingesting the commercial
tablet containing 20 mg of LF, 2.6 mg of LPO, and
2.6 mg of GO than the placebo tablet. These results sug-
gested that the efficacy of this commercial tablet, which
had less LF, in suppressing oral malodor was similar to
that of the previous trial tablet in the short term.
A limitation of our study is the slight difference in
taste between the tablets, which was due to their ingre-
dients. Although our subjects may have been able to
distinguish between these tablets, they were unable to
control the concentrations of VSCs measured by Oral-
Chroma. Therefore, we considered the robustness
against a measurement bias to have been sustained.
The treatment effects of the test tablet on total VSCs
and H2S did not differ when subjects were fractionated
by sex and age. Furthermore, a correlation was not ob-
served between age and the treatment effect on VSCs. A
previous survey reported no significant differences in
VSCs between males and females or among ages [31]. It
appears reasonable to extrapolate the results obtained in
the present study to general populations.
The reducing effect on total VSCs positively correlated
with PPD. These results suggested that treatment effects
were greater in subjects with deep periodontal pockets.
Tanaka et al. found positive coefficients between the per-
centages of probing pocket depth ≥ 4 mm and the popu-
lation of periodontal pathogens including P. gingivalis
on the tongue dorsum, and the population of these path-
ogens positively correlated with the concentration of
total VSCs [32]. In the present study, subjects with deep
pocket depths may have had a larger population of VSC-
producing bacteria, which are considered the target of
LF and the LPO system.
In order to allow active ingredients to function effect-
ively in the mouth, subjects were asked to suck the tab-
lets without biting or swallowing them. The time for
tablets to dissolve completely was approximately 3 to
11 min. We investigated the influence of the sucking
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time of the test tablet on suppressing the concentration
of VSCs. The sucking time did not interact with the
treatment effects. These results suggested that the sup-
pressing effects on oral malodor occurred when the sub-
ject sucked the test tablet for at least 3 min. In a
previous in vitro study, a composition containing LPO,
GO, glucose, and SCN− reduced the number of A. acti-
nomycetemcomitans by more than 1 log unit after
3.75 min [19], and was found to inactivate the bacterial
lyase related to VSC production after 10 min [21]. These
in vitro bactericidal and inactivating effects in a short
time period may contribute to the immediate effects of
the test tablet on oral malodor.
No adverse events related to the treatment were ob-
served in any of the 40 subjects during the study. All in-
gredients in the current test tablet including LF, LPO,
and GO have been permitted as a food or food additive
in Japan. Furthermore, the long-term ingestion of previ-
ous trial tablets containing LF (300 mg/day), LPO
(5.4 mg/day) and Sumizyme PGO (72 mg/day) for
12 weeks had no adverse events in general or on the oral
condition [33]. Therefore, the test tablet in the present
study may be continuously and safely taken on a daily
basis.
Severe or long-standing oral malodor has a negative
impact on self-confidence and social interactions [1].
Therefore, a daily treatment for oral malodor is consid-
ered important. A previous study demonstrated that
VSC concentrations decreased after a meal and then
gradually increased between meals [23]. Since the test
tablet has excellent portability and immediately sup-
presses oral malodor, it has potential as a daily treat-
ment, particularly for suppressing VSCs between meals.
Furthermore, VSCs have been shown to affect the pro-
gression of periodontal disease [5–7]. The long-term
administration of this tablet may potentially contribute
to maintaining the oral hygiene status.
Conclusions
The results of the present clinical trial suggested that
the single ingestion of a tablet containing 20 mg of LF,
2.6 mg of LPO, and 2.6 mg of GO exhibited suppressive
effects on VSCs in mouth air in the general population.
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